Equities

NuCana PLC

NuCana PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.00
  • Today's Change-0.03 / -0.99%
  • Shares traded11.52k
  • 1 Year change-84.00%
  • Beta1.0173
Data delayed at least 15 minutes, as of Jun 14 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

  • Revenue in USD (TTM)0.00
  • Net income in USD-33.74m
  • Incorporated1997
  • Employees25.00
  • Location
    NuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
  • Phone+44 131 248 3660
  • Fax+44 131 248 3001
  • Websitehttps://www.nucana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TFF Pharmaceuticals Inc885.71k-19.93m6.01m19.00--0.9214--6.79-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
Hepion Pharmaceuticals Inc0.00-38.52m6.07m22.00--1.04-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
Notable Labs Ltd311.00k-12.39m6.13m16.00--0.5312--19.72-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Tenax Therapeutics Inc0.00-10.10m6.15m5.00--0.4947-----24.52-24.520.006.350.00----0.00-67.96-199.16-75.66-285.64-----------105.120.0322------30.21------
Glucose Health Inc1.11m-456.46k6.19m2.00--6.53--5.56-0.033-0.0330.08030.0561-----------86.94---153.9547.1940.68-31.99-56.93313.11--0.00--98.3924.9416.87------
BioCardia Inc468.00k-10.34m6.21m16.00------13.26-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
GT Biopharma Inc0.00-9.64m6.23m2.00--0.7513-----7.04-7.040.003.850.00----0.00-64.24-205.36-90.39--------------0.00------63.62------
Kineta Inc5.16m-17.89m6.24m11.00------1.21-1.55-1.550.4673-0.5640.6667----469,181.80-230.51-66.16---86.61-----345.77-854.74--------178.6513.8977.76------
Sunshine Biopharma Inc26.74m-4.09m6.25m44.00--0.0132--0.2338-13.35-13.3576.9624.960.90813.1311.58607,722.50-13.88-101.52-17.99-137.0433.1535.47-15.29-165.333.23--0.00--454.42--83.15--110.99--
NuCana PLC (ADR)0.00-33.74m6.34m25.00--0.5312-----301.53-301.530.005.650.00----0.00-72.34-41.01-125.17-48.07------------0.0324------13.71---21.70--
Titan Pharmaceuticals Inc87.00k-4.95m6.34m4.00--1.04--72.93-6.41-6.410.11196.660.0197--1.2321,750.00-112.41-96.80-170.59-156.65-----5,694.25-406.26---415.190.00---66.97-51.1645.43---65.61--
Intelligent Bio Solutions Inc2.83m-10.03m6.42m17.00--0.5392--2.27-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Virios Therapeutics Inc0.00-5.07m6.61m4.00---------0.2673-0.26730.00--------------------------------------56.76------
22nd Century Group Inc29.75m-62.89m6.70m64.00------0.2252-40.02-97.9317.94-3.230.405.905.47464,796.90-66.29-46.78-92.49-54.18-33.09-2.11-165.75-107.950.4284-3.674.76---20.494.03-76.94--53.60--
Integrated BioPharma, Inc.50.57m-116.00k6.72m141.00--0.355231.680.1328-0.0041-0.00411.670.62831.884.4510.76358,617.00-0.43115.51-0.569827.947.0912.09-0.22946.441.02-9.000.001---9.913.00-101.35---14.03--
Data as of Jun 14 2024. Currency figures normalised to NuCana PLC's reporting currency: US Dollar USD

Institutional shareholders

2.79%Per cent of shares held by top holders
HolderShares% Held
Acadian Asset Management LLCas of 31 Mar 202423.63k1.14%
Renaissance Technologies LLCas of 31 Mar 202416.83k0.81%
HRK LUNIS AGas of 30 Dec 20228.80k0.43%
Citadel Securities LLCas of 31 Mar 20243.57k0.17%
HRT Financial LLCas of 31 Mar 20241.34k0.07%
Edmond de Rothschild (Suisse) SA (Private Banking)as of 31 Mar 20241.00k0.05%
Horizon Kinetics Asset Management LLCas of 31 Mar 2024779.000.04%
Geode Capital Management LLCas of 31 Mar 2024751.000.04%
G1 Execution Services LLCas of 31 Mar 2024566.000.03%
BNP Paribas Financial Marketsas of 31 Mar 2024500.000.02%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.